Gosuke Homma

Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial ( <scp>EMPA‐ELDERLY</scp> )

Daisuke Yabe, Kosuke Shiki, Gosuke Homma et al. · Diabetes Obesity and Metabolism · 2023 · 79 citations · Full text

Medicine, Geriatric Medicine, Pharmacotherapy +17

Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients

Fumihiko Sakai, Takao Takeshima, Gosuke Homma et al. · Headache The Journal of Head and Face Pain · 2021 · 47 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Ramucirumab or placebo plus erlotinib in <i>EGFR</i>‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

Makoto Nishio, Takashi Seto, Martin Reck et al. · Cancer Science · 2020 · 39 citations · Full text

Medicine, Oncology, Pharmacology +17

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial

Masatoshi Kudo, Takuji Okusaka, Kenta Motomura et al. · Journal of Gastroenterology · 2020 · 33 citations · Full text

Medicine, Oncology, Pharmacology +16

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

Kazuto Nishio, Takashi Seto, Makoto Nishio et al. · JTO Clinical and Research Reports · 2021 · 12 citations · Full text

Medicine, Oncology, Pharmacotherapy +12